arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lipocine Inc.

LPCN
$1.52 ▲ +0.06 (+4.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lipocine Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.5M
Dividend Yield —
Revenue Growth -69.5% ↘
Op. Margin None
ROIC -13.1% →
FCF / Share $-0.37 ↘
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$190.10K
↓ -69.5% —
Net Income Profit after all expenses
$-2.62M
↓ -18.9% —
Operating Margin Operating profit as % of sales
-219.6%
↑ +43.1% —
FCF / Share Free cash flow per share
$-0.37
↓ -11.0% —
Long-Term Debt Long-term obligations
$833.00K
↓ -66.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
13
Cash Quality ↓
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 62 quarters